Vanguard Asset Management
LEGN icon

Vanguard Asset Management’s Legend Biotech LEGN Stock Holding History

Vanguard Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.94M Hold
136,489
– – ﹤0.01% 1180
2026
Q1 		$2.47M Buy
+136,489
New +$2.6M ﹤0.01% 1362

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Vanguard Asset Management's LEGN Position: Q2 2026 in Review

Vanguard Asset Management held its Legend Biotech (LEGN) position steady in Q2 2026 at 136,489 shares worth $3.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1180.

Vanguard Asset Management first reported a position in LEGN in Q1 2026 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Vanguard Asset Management held 136,489 shares of Legend Biotech worth $3.94M as of Q2 2026.
  • Vanguard Asset Management left its Legend Biotech share count unchanged in Q2 2026.
  • Legend Biotech made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1180 holding.
  • Vanguard Asset Management first reported a position in Legend Biotech in Q1 2026 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.